Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

InnoCan Pharma (INNO) Stock Price & Analysis

23 Followers

INNO Stock Chart & Stats

CA$1.90CA$0.00(0.00%)
At close: 4:00 PM EST
C$1.75C$2C$2.25C$2.5Aug 10Aug 24Sep 8Sep 21Oct 6Oct 15Nov 3
Day’s Range
CAD 1.90 - CAD 1.90
52-Week Range
CAD 1.60 - CAD 19.15
Previous Close
CAD 1.90
Volume
N/A
Average Volume (3M)
540
Market Cap
CAD 8.55M
Enterprise Value
CAD 8.16M
Total Cash (Recent Filing)
CAD 6.44M
Total Debt (Recent Filing)
CAD 1.66M
Price to Earnings (P/E)
―
Beta
-0.71
Next Earnings
Dec 02, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Gross Margins

Gross margins near 90% indicate favorable economics on the products currently being sold and provide meaningful room to cover operating costs. If maintained, this profitability at the product level can support investment in pharmaceutical development and improve earnings leverage as revenue stabilizes.

Moderate Leverage

Moderate leverage and positive equity provide some financial support while the company works toward profitability. This balance-sheet position is less restrictive than a highly leveraged structure, preserving greater flexibility to fund operations, develop products, and manage ongoing business volatility.

Multiple Revenue Pathways

Combining current cannabinoid product sales with regulated pharmaceutical and drug-delivery development creates more than one potential route to long-term value. Commercial products can provide an operating base, while successful pipeline advancement could add licensing or commercialization opportunities.

Bears Say

Unprofitability And Revenue Decline

The company has not yet converted its strong gross margins into sustainable profitability, and declining revenue reduces operating leverage. Continued weakness could make fixed expenses harder to absorb, delay the path to earnings, and limit internally funded investment in its pharmaceutical pipeline.

Current Cash Burn

Negative operating and free cash flow show that the business is currently consuming cash rather than funding itself. Persistent cash burn can increase dependence on external financing, constrain research and commercial investment, and heighten execution risk while the company remains loss-making.

Rising Leverage And Negative Returns

Although leverage remains moderate, its upward direction alongside negative returns on equity signals deteriorating capital efficiency. If losses and cash consumption continue, additional debt could become more important to operations, increasing financial pressure and reducing flexibility for strategic investment.

InnoCan Pharma News

INNO FAQ

What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was C$1.60 and its highest was C$19.15 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is C$8.55M.
When is InnoCan Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on Aug 31, 2026. The company reported -C$0.01 earnings per share for the quarter.
Is InnoCan Pharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -C$0.01 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in TSE:INNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology